# Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-chemotherapy-in-epidermal-growth-factor/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tony Mok,Sang‐We Kim,Yi‐Long Wu,Kazuhiko Nakagawa,Jin‐Ji Yang,Myung‐Ju Ahn,Jie Wang,James Chih‐Hsin Yang,You Lü,Shinji Atagi,Santiago Ponce,Xiaojin Shi,Yuri Rukazenkov,Vincent Haddad,Kenneth S. Thress,Jean‐Charles Soria |
| Citations | 188 |
| DOI | 10.1200/jco.2017.73.9250 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2762423488 |
| PMID | 28968167 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Myung‐Ju Ahn](https://scholariq.org/researchers/myung-ju-ahn/)
- [Kenneth S. Thress](https://scholariq.org/researchers/kenneth-s-thress/)
- [James Chih‐Hsin Yang](https://scholariq.org/researchers/james-chih-hsin-yang/)
- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.